Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00458016 | Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus | PHASE2 | COMPLETED | 105 | — | — | Mar 1, 2007 | Mar 1, 2008 | Oct 3, 2011 | 25 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MB07803 | DRUG | Daily oral administration |
| Placebo | DRUG | Daily oral administration |
Inclusion Criteria: * Fasting plasma glucose between 120 - 270 mg/dL at screening * HbA1c measurements between 6.0 - 10% at screening * Females who are surgically sterile (i.e. women who have had a hysterectomy or tubal ligation). Females who are postmenopausal for at least 12 consecutive months an...